Scynexis
-
Contamination Risk Sparks a Recall of GSK, Scynexis Antifungal Drug
Scynexis said no adverse events or contamination problems have been reported for Brexafemme, an antifungal approved for treating vaginal yeast infections. The biotech said the risk of cross-contamination stems from the processes of the small molecule’s third-party manufacturer.
-
GSK Strikes Another Antimicrobial Deal, Paying $90M for Scynexis’s Brexafemme
GSK acquired global rights to Brexafemme, a novel antifungal from Scynexis that is approved for treating vaginal yeast infections. The deal also gives GSK the chance to commercialize the drug in other indications.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Scynexis antifungal drug secures FDA nod; first approval in new class in 20 years
The FDA has approved Brexafemme, a Scynexis antifungal drug, for treating vaginal yeast infections. The drug is the biotech’s first FDA-approved product and it also represents the first new antifungal drug class in 20 years.
-
New antibiotics are urgently needed, but economics stand in the way
In the wake of Achaogen’s bankruptcy, experts discussed ways to ensure new treatments are available to combat drug-resistant bacteria that threaten a post-antibiotic world.
-
With hepatitis C compound in phase 2, Scynexis raises $11.5M of $15M target
Drug discovery and development company Scynexis, which is in midstage clinical development of a novel […]
-
Life sciences companies make pharma pitches, hope for hits with investors
Life sciences companies presenting at CED’s Life Science Conference largely stuck to script. Prepared remarks. […]
-
Scynexis aims to raise $15M; hepatitis C drug candidate in phase 2 trials
Drug discovery and development firm Scynexis, which is moving forward on a new hepatitis C […]
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
